1. Janossy G et al. (1981) Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 17: 839–842
2. Panayi GS (1995) The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics. Agents Actions Suppl 47: 1–21
3. Choy EHS et al. Immunotherapies: T cell, B cell and complement. In Rheumatology, edn 3, 449–454 (Eds Hochberg MC et al.) Philadelphia: Mosby
4. Choy EH et al. (2002) Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 41: 1142–1148
5. Mason U et al. (2002) CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 29: 220–229